undamentalytics Newsletter
Sign in

Taysha Gene Therapies, Inc. revenue

Taysha Gene Therapies, Inc.'s revenue was $9.8m in fiscal 2025, up 17.3% on the year before. Since fiscal 2022 ($2.5m) it has grown at a compound 57.5% a year. Over the last twelve months it was $5.5m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue3158105
Growth on the year before—+517.5%−46.1%+17.3%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Taysha Gene Therapies, Inc. $5.5m -32.3% —
Immuron Ltd $5.2m 10.9% —
Inventiva S.a. $5.1m -49.1% —
Adlai Nortye Group Ltd. $5.0m — —
Rani Therapeutics Holdings, Inc. $4.9m 306.4% —
CG Oncology, Inc. $6.2m 1030.3% —

Compare with peers

Head to head: IMRN vs TSHAIVA vs TSHAANL vs TSHACGON vs TSHA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Taysha Gene Therapies, Inc.